Formulary

Advocates, Clinicians Urge CVS Caremark to Reverse Dangerous Formulary Change

Retrieved on: 
Thursday, December 16, 2021

The move would force stable patients to switch medications, a practice known as non-medical switching , and increase their risk of stroke and death.

Key Points: 
  • The move would force stable patients to switch medications, a practice known as non-medical switching , and increase their risk of stroke and death.
  • The medications require careful, personalized management, and indiscriminate switching can cause severe side effects and lead patients to discontinue treatment altogether.
  • Studies about the discontinuation of these drugs have shown that:
    This new formulary change will be dangerously disruptive for patients who rely upon a previously covered direct oral anticoagulant to manage their cardiovascular risk.
  • STATEMENT FROM DHARMESH PATEL, MD, STERN CARDIOVASCULAR CENTER, MEMPHIS TENNESSEE AND PRESIDENT, PARTNERSHIP TO ADVANCE CARDIOVASCULAR HEALTH:
    "The removal of these critical therapies from CVS Caremark's formulary is putting lives at risk.

LifeServe Blood Center Receives Envi® Best Practice Award

Retrieved on: 
Tuesday, December 14, 2021

ALISO VIEJO, Calif., Dec. 14, 2021 /PRNewswire-PRWeb/ --LifeServe Blood Centers has received the Envi Best Practice Award for excellence in item master and inventory management.

Key Points: 
  • ALISO VIEJO, Calif., Dec. 14, 2021 /PRNewswire-PRWeb/ --LifeServe Blood Centers has received the Envi Best Practice Award for excellence in item master and inventory management.
  • As Envi team members work with supply chain leaders across the U.S., they have ongoing opportunities to recognize those successfully creating and implementing new best practice processes.
  • Accurate min/max levels based on history, market-specific activities (i.e., blood drives)
    "We are honored to recognize the team at LifeServe Blood Centers for their end-to-end supply chain improvements," said Steve Britt, Senior Vice President, Envi.
  • This Best Practice Award recognizes the team for their commitment to ongoing improvement, enterprise-wide change management and their advancement of supply chain automation."

Alio Announces Partnership with Lifeline for Dialysis Access Patient Monitoring

Retrieved on: 
Wednesday, December 1, 2021

Alio leverages artificial intelligence and its SmartPatch sensor technology to non-invasively monitor vascular access health and other chronic conditions faced by ESRD patients.

Key Points: 
  • Alio leverages artificial intelligence and its SmartPatch sensor technology to non-invasively monitor vascular access health and other chronic conditions faced by ESRD patients.
  • Key partnership metrics are based on the improvement of quality of life and the overall patient care experience.
  • Overall, the partnership with Alio and Lifeline will support Alio's growth objectives and its overarching goal of improving patient outcomes by enabling physicians to deliver the best patient care possible.
  • Alio's remote patient monitoring solution, which features their proprietary SmartPatch technology, leverages artificial intelligence to monitor multiple chronic conditions.

Alio Announces Partnership with Lifeline for Dialysis Access Patient Monitoring

Retrieved on: 
Wednesday, December 1, 2021

Alio leverages artificial intelligence and its SmartPatch sensor technology to non-invasively monitor vascular access health and other chronic conditions faced by ESRD patients.

Key Points: 
  • Alio leverages artificial intelligence and its SmartPatch sensor technology to non-invasively monitor vascular access health and other chronic conditions faced by ESRD patients.
  • Key partnership metrics are based on the improvement of quality of life and the overall patient care experience.
  • Overall, the partnership with Alio and Lifeline will support Alio's growth objectives and its overarching goal of improving patient outcomes by enabling physicians to deliver the best patient care possible.
  • Alio's remote patient monitoring solution, which features their proprietary SmartPatch technology, leverages artificial intelligence to monitor multiple chronic conditions.

RedHill Biopharma's Movantik® Added as Preferred and Unrestricted Brand To Major National Medicare Formulary Serving Millions of Americans

Retrieved on: 
Wednesday, December 1, 2021

"This important new listing for Movantik, the market-leading PAMORA for opioid-induced constipation, as a preferred and unrestricted brand on a major National Medicare Part D formulary provides that access to more than 10 million more Americans covered by this formulary.

Key Points: 
  • "This important new listing for Movantik, the market-leading PAMORA for opioid-induced constipation, as a preferred and unrestricted brand on a major National Medicare Part D formulary provides that access to more than 10 million more Americans covered by this formulary.
  • Patients with known or suspected gastrointestinal (GI) obstruction and patients at risk of recurrent obstruction, due to the potential for GI perforation.
  • Patients with a known serious or severe hypersensitivity reaction to Movantik or any of its excipients.
  • Symptoms consistent with opioid withdrawal, including hyperhidrosis, chills, diarrhea, abdominal pain, anxiety, irritability, and yawning, occurred in patients treated with Movantik.

Avicanna Expands its Medical Cannabis Brand RHO Phyto into the Caribbean Region with Initial Export to Barbados

Retrieved on: 
Thursday, November 25, 2021

The Company plans to deliver the RHO Phyto products to the medical community and patients in the Caribbean through Bryden Stokes extensive network and sales infrastructure in the region starting with Barbados.

Key Points: 
  • The Company plans to deliver the RHO Phyto products to the medical community and patients in the Caribbean through Bryden Stokes extensive network and sales infrastructure in the region starting with Barbados.
  • In Barbados, specifically, the products will be commercialized under the Medicinal Cannabis Industry Act 2019-44 which outlines regulation of the handling of medicinal cannabis on the island.
  • We look forward to establishing RHO Phyto as the gold standard throughout the region and aim to build long-term opportunities for the brand.
  • Bryden Stokes is delighted to commence a partnership with Avicanna to provide pharmaceutical-grade medicinal cannabis to patients in Barbados and the Eastern Caribbean; specifically, the Rho Phyto brand of products.

China sees huge bounce in pharma rankings ahead of hybrid CPhI & P-MEC China

Retrieved on: 
Thursday, November 18, 2021

The China specific findings of the CPhI Annual Report rankings[1] are released ahead of CPhI & P-MEC China- which will take place in hybrid form, with Virtual Expo Connect running digitally from November 18th until December 18th, and the in-person event held at the Shanghai New International Expo Center (SNIEC)December 16-18th, 2021.

Key Points: 
  • The China specific findings of the CPhI Annual Report rankings[1] are released ahead of CPhI & P-MEC China- which will take place in hybrid form, with Virtual Expo Connect running digitally from November 18th until December 18th, and the in-person event held at the Shanghai New International Expo Center (SNIEC)December 16-18th, 2021.
  • Collectively, the hybrid event is expected to welcome 50,000 attendees, 2,000+ exhibitors and features a personalised hosted buyer programmefor qualified international buyers from more than 20 countries.
  • Chemical precursors are not always involved in the GMP portion of the API synthesis and can easily be incorporated from third-party suppliers.
  • CPhI hosts events in Europe, Korea, China, India, Japan, South East Asia, North America, and the Middle East and Africa.

DGAP-News: ​​​​​​​PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST NINE MONTHS OF 2021

Retrieved on: 
Wednesday, November 10, 2021

Procedural sedation: Remimazolam (brand name Byfavo(R)) received market approval in the EU (including EEA countries) in March 2021 and in the United Kingdom in June 2021.

Key Points: 
  • Procedural sedation: Remimazolam (brand name Byfavo(R)) received market approval in the EU (including EEA countries) in March 2021 and in the United Kingdom in June 2021.
  • The overall evaluation of opportunities and risks has not changed significantly in the first nine months of 2021.
  • PAION confirms its financial outlook for the current fiscal year announced on 23 August 2021 with the publication of the half-year results for 2021.
  • In addition, PAION plans to submit the MAA for remimazolam for general anesthesia in Europe by the end of 2021.

Agile Therapeutics Reports Third Quarter 2021 Financial Results

Retrieved on: 
Tuesday, November 2, 2021

PRINCETON, N.J., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today reported financial results for the three months ended September 30, 2021 and provided a corporate update.

Key Points: 
  • Management to Host Conference Call Today, Tuesday, November 2, 2021 at 4:30 p.m. EDT
    PRINCETON, N.J., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc.(Nasdaq: AGRX), a women's healthcare company, today reported financial results for the three months ended September 30, 2021 and provided a corporate update.
  • Recent Corporate Developments and Third Quarter 2021 Results:
    During the third quarter 2021, total cycles dispensed were 9,747, representing an increase of 61% from the end of the second quarter.
  • Total prescriptions in the third quarter 2021 were 7,374, representing an increase of 47% from the end of the second quarter.
  • In the third quarter 2021, the Company announced a partnership with Pandia Health, a telehealth service provider, which is now active.

Purchaser Business Group on Health Launches New Company, Emsana Health, to Develop Solutions that Meet the Specific Needs of Large Employers

Retrieved on: 
Monday, October 25, 2021

EmsanaRx is structured to address the lack of accountability of the PBM industry to its employer clients, who largely lack access to information about drug costs, true discounts and administrative fees that contribute to huge profits -- predominantly for three PBMs dominating 80% of the market. Developed by PBGH with the backing of its members, EmsanaRx’s business incentives are structured to align with the interests of the large employers paying the bills.

Key Points: 
  • Emsana Health and its first business unit, EmsanaRx, are a natural outgrowth of PBGHs 30-plus years of work redesigning health care markets to reflect our members priorities.
  • Emsana Health is an innovation studio working with large employers to design and build products and tools that address their unique health care needs.
  • Emsana Health works closely with large employers to identify solutions to health care challenges, partner with experienced health care entrepreneurs and leverage technology to build products that can scale across multiple employers.
  • Emsana Health wasfounded by the Purchaser Business Group on Health to develop and advance products that tackle some of the biggest problems large employers face with health care.